Jay S. Duker, M.D., is the Director of the New England Eye Center (NEEC), one of the largest academic, multi-specialty ophthalmology practices in the United States, and Professor and Chairman of the Department of Ophthalmology at Tufts Medical Center and the Tufts University School of Medicine in Boston. Jay received his medical degree magna cum laude from Jefferson Medical College. He completed both his ophthalmology residency and his two year fellowship in vitreo-retinal diseases at the Wills Eye Hospital in Philadelphia. His clinical practice is limited to medical and surgical diseases of the posterior segment with particular emphasis on macular diseases, posterior uveitis and intraocular tumors.

He has published over 200 journal articles, with his major research interests, which include retinal imaging and in particular, optical coherence tomography (OCT), retinal vascular diseases and drug delivery to the posterior segment. His book, Yanoff and Duker’s Ophthalmology, is one of the best-selling ophthalmic texts over the past decade. Jay is the editor-in-chief of the International Journal of Retina and Vitreous (IJRV) and serves on the editorial board of OSLI Retina and IOVS. Jay is the co-founder of three companies, including Hemera Biosciences, a biotech start-up whose focus is a gene-therapy-based treatment for age-related macular degeneration. He is also a Director of Eleven Biotherapeutics, a publicly traded clinical-stage protein engineering company.

Evangelos Gragoudas is a leading clinician-researcher and has spent over 25 years investigating treatments for intraocular tumors and macular disorders. He has been the Director of Retina Service at the Massachusetts Eye and Ear Infirmary since 1985. Evangelos is considered a world authority on the diagnosis and management of ocular tumors and is world-renowned for his groundbreaking work in the use of proton irradiation to treat intraocular melanoma. He and his colleagues pioneered the development of photodynamic therapy for neovascular age-related macular degeneration. Evangelos has published over 200 articles in peer-reviewed journals and written or authored more than 100 chapters, reviews and books; he lectures nationally and internationally. He completed his medical training in Athens, Greece, and his ophthalmology residency at Boston University School of Medicine.

Evangelos is the recipient of several major awards and honors, including the esteemed Mildred Weisenfeld Award for Excellence in Ophthalmology from the Associate for Research in Vision and Ophthalmology for his invaluable contributions to the field of ocular oncology and the development of vascular-targeting therapies from numerous eye disorders.

Brian Marr has 14 years of experience in ocular oncology and is currently Director of the Ophthalmic Oncology service at Columbia University Medical Center. Additionally, Brian is a member of the ophthalmic oncology team at Memorial Sloan-Kettering Cancer Center. He previously served as Assistant Attending Surgeon and Associate Attending Surgeon at Wills Eye Hospital in Philadelphia. Before that, he served as Clinical Assistant Surgeon at Albert Einstein Medical Center. Brian received his BS in Biology from Albright College and his M.D. from Temple University Medical School. Brian completed his postdoctoral training at Crozer-Chester Medical Center and New York Eye and Ear Infirmary, as well as a fellowship at Wills Eye Hospital.

Brian has been twice recognized as a “Top Doctor” by New York Magazine. He has authored nearly 100 peer-reviewed publications and manuscripts.

Carol L. Shields practices ocular oncology at and is currently Co-Director of the Oncology Service at Wills Eye Hospital. She is also a Professor of Ophthalmology at Thomas Jefferson University in Philadelphia. She previously was the first elected President of the International Society of Ocular Oncology, the largest international society of clinicians and basic scientists interested in ocular tumors. Carol completed her residency in ophthalmology at Wills Eye Hospital in Philadelphia and subsequently did fellowship training in Ocular Oncology, Oculoplastic Surgery and Ophthalmic Pathology.

She has authored or co-authored 12 textbooks, over 1400 articles in major journals and over 300 textbook chapters as well as given over 700 lectureships. Carol has received numerous professional awards, including the Donders Award in 2003, given by the Netherlands Ophthalmological Society; an Honorary Doctorate of Science Degree each from the University of Notre Dame in 2005 and the Catholic University in 2011; and the American Academy of Ophthalmology Life Achievement Honor Award in 2011. Carol is also a member of numerous ocular oncology, pathology and retina societies and has delivered more than 35 named lectures in America and abroad. She has been active in the American Academy of Ophthalmology and serves on the editorial board of several journals, including Retina, Journal of Pediatric Ophthalmology and Strabismus, Ophthalmic Plastic and Reconstructive Surgery, and International Journal of Clinical Oncology.

Arun D. Singh is the Director of the Department of Ophthalmic Oncology in the Cole Eye Institute at the Cleveland Clinic. He has specialty interests in ophthalmic tumors in adults and children, with research interests in uveal melanoma, the genetics of retinoblastoma, retinal capillary hemangioma and von Hippel-Lindau disease. Arun completed fellowships in Ophthalmology at Watford General Hospital in the United Kingdom and in Ocular Oncology at Wills Eye Hospital in Philadelphia. He earned his BS at the University of Madras in Nadu, India, and his M.D. at the Jawaharlal Institute of Post Graduate Medical Education and Research in Pondicherry, India.

He is Fellow of the Royal College of Ophthalmologists, London, and the American Board of Ophthalmology. Arun has published more than 300 scientific articles in peer-reviewed journals and has edited several textbooks. He is Editor of Ocular Oncology and Pathology. Arun has earned an Achievement Award from the American Academy of Ophthalmology.

Dr. Schiller is Deputy Chief and Head of the Neoplastic Disease Section, Laboratory of Cellular Oncology at the National Cancer Institute, NIH, and an NIH Distinguished Investigator. He has received numerous awards for his contributions to papillomavirus virus molecular biology and HPV vaccine development, including the Lasker DeBakey Award in 2017, the American Society for Microbiology’s Joseph Public Health Award in 2014, and National Medal of Technology and Innovation in 2014. Dr. Schiller graduated from the University of Wisconsin-Madison with a B.S. in molecular biology and received a Ph.D. from the Department of Microbiology of the University of Washington in Seattle.

David is a biopharmaceutical business leader with more than 25 years of experience in drug development. He is currently Chief Executive Officer and founder of Solve Therapeutics, a venture-backed start-up focusing on developing next-generation mAb-based oncology therapeutics. In late 2021, the company closed a $126 million Series A financing.

Prior to founding Solve Therapeutics, David served as Chief Executive Officer at VelosBio, which Merck acquired for $2.75 billion in late 2020. Before VelosBio, David was Chief Executive Officer at Acerta Pharma, where he led the company through a critical phase of growth from early to late-stage clinical development. David and his leadership team ultimately led the acquisition of Acerta by AstraZeneca in a deal valued at $7 billion.

Prior to Acerta, David held roles of increasing responsibility with Calistoga (acquired by GILD), Gloucester (acquired by CELG), MLMN (acquired by TAK), Immunex (acquired by AMGN), and Roche. He has raised over $700 million in biopharma capital and delivered transactions valued at over $10 billion.

In addition to Aura’s Board, David serves on the Board of Directors of Palleon Pharmaceuticals and Lengo Therapeutics (recently acquired by BPMC). He also serves as the Chairman of the Board of Directors of Zentalis Pharmaceuticals­, a publicly traded clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancer.

Jeremy most recently served as Chief Executive Officer, President and a member of the board of directors of Day One Biopharmaceuticals, where he led the company through its evolution into a commercial-stage oncology company, including the approval and launch of OJEMDA® for pediatric low-grade glioma and the company’s approximately $2.5 billion acquisition by Servier in 2026. Prior to joining Day One, he served as Vice President of Corporate Development at Gilead Sciences. Earlier in his career, Jeremy held executive leadership positions at Tizona Therapeutics, Sutro Biopharma and Allos Therapeutics, where he led corporate strategy, business development and operational execution. He began his career in the life sciences practice at Boston Consulting Group. Jeremy currently serves as an independent member of the board of directors of Mereo BioPharma Group plc. He previously served on the board of directors of Fusion Pharmaceuticals, Inc. He earned a B.S. in Biological Sciences from Stanford University, a Ph.D. in Microbiology and Immunology from the University of Colorado, and an M.B.A. from the MIT Sloan School of Management.

Teresa is currently the President of the Global Oncology Business Unit and a member of the Executive Team at Takeda, where she oversees a global portfolio of therapies targeting gastrointestinal, thoracic, and hematological cancers. In this role, Teresa leads all aspects of Takeda’s multi-billion-dollar oncology business, with major markets in the US, Europe, and Japan. Before joining Takeda, Teresa was Senior Vice President and Head of Worldwide Oncology Commercialization at Bristol Myers Squibb (BMS). She held leadership roles of increasing responsibility at BMS, including in infectious diseases and neuroscience. She served as Senior Vice President and Head of U.S. Oncology, President and General Manager of BMS Canada, and Worldwide Head of BMS Virology. Prior to BMS, Teresa was part of the Capital Markets Group at Mobil Oil Corporation, overseeing the investment of Mobil’s worldwide pension assets. In addition to her role at Takeda, Teresa serves on the Board of Directors for Osmol Therapeutics, which is focused on developing a treatment to prevent chemotherapy-induced peripheral neuropathy. Teresa earned her MBA from the Darden School of Business at the University of Virginia and her BA from Wellesley College.

Natalie has served as Chief Executive Officer of Aura Biosciences since April 2026. She has more than 25 years of executive leadership, business development, corporate strategy, and commercial experience gained in a range of therapeutic areas. Prior to Aura, Natalie served as CEO of Third Harmonic Bio from August 2021 through December 2025. Prior to Third Harmonic, Natalie served as President and Chief Executive Officer of Audentes Therapeutics (acquired by Astellas in 2020). She joined Audentes as Senior Vice President and Chief Operating Officer in August 2015 and was subsequently promoted to President and Chief Operating Officer in May 2018, and then to President and Chief Executive Officer in January 2020. Prior to joining Audentes, Natalie served as Senior Vice President, Corporate Development at Hyperion Therapeutics (acquired by Horizon Pharma in 2015). Before that, she provided executive-level strategy and business development advisory services to a number of privately held biopharmaceutical companies. Earlier in her career, Natalie served as Vice President, Business Development at KAI Pharmaceuticals (acquired by Amgen in 2012) and held corporate development and commercial roles at InterMune (acquired by Roche in 2014) and Genentech.

Natalie holds an AB in human biology from Stanford University and an MA in molecular, cellular and developmental biology from the University of Colorado, Boulder, where she was a Howard Hughes Medical Institute predoctoral fellow.